Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload

Journal of the American College of Cardiology

Volumn 69, Issue 11, 2017, Pages 1409-1419

  Konstam, Marvin A ^a   Kiernan, Michael ^a   Chandler, Arthur ^b   Dhingra, Ravi ^c   Mody, Freny Vaghaiwalla ^d   Eisen, Howard ^e   Haught, W Herbert ^f   Wagoner, Lynne ^g   Gupta, Divya ^h   Patten, Richard ⁱ   Gordon, Paul ^j   Korr, Kenneth ^j   Fileccia, Russell ^k   Pressler, Susan J ^l   Gregory, Douglas ^m   Wedge, Patricia ^m   Dowling, Douglas ^m   Romeling, Matthew ^m   Konstam, Jeremy M ^m   Massaro, Joseph M ⁿ   Udelson, James E ^a   more..

^a TUFTS MEDICAL CENTER   (United States)

^b University Cardiology Associates   (Georgia)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e DREXEL UNIVERSITY   (United States)

^f Heart Center Research   (United States)

^g Mercy Hospital   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^j MIRIAM HOSPITAL   (United States)

^k Advanced Cardiovascular Specialists   (United States)

^l INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

^m Cardiovascular Clinical Science Foundation   (United States)

ⁿ BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

clinical trials; diuresis; dyspnea; jugular venous pressure; vasopressin antagonism

Indexed keywords

PLACEBO; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; AGED; ARTICLE; ASCITES; CLINICAL OUTCOME; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPNEA; ELEVATED BLOOD PRESSURE; ELEVATED JUGULAR VENOUS PRESSURE; FEMALE; HEART FAILURE; HUMAN; HYPERNATREMIA; HYPERVOLEMIA; HYPOTENSION; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WEIGHT REDUCTION; CLINICAL TRIAL; MIDDLE AGED; VERY ELDERLY; WATER-ELECTROLYTE IMBALANCE;

AGED; AGED, 80 AND OVER; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; WATER-ELECTROLYTE IMBALANCE;

EID: 85015205277     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.12.035     Document Type: Article

References (22)

1. 1 Heidenreich, P.A., Albert, N.M., Allen, L.A., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6 (2013), 606–619.
2. 2 Damman, K., Navis, G., Voors, A.A., et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13 (2007), 599–608.
3. 3 Klein, L., O'Connor, C.M., Leimberger, J.D., et al., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111 (2005), 2454–2460.
4. 4 Testani, J.M., Chen, J., McCauley, B.D., Kimmel, S.E., Shannon, R.P., Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122 (2010), 265–272.
5. 5 Hasselblad, V., Gattis Stough, W., Shah, M.R., et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 9 (2007), 1064–1069.
6. 6 Udelson, J.E., Smith, W.B., Hendrix, G.H., et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001), 2417–2423.
7. 7 Udelson, J.E., Orlandi, C., Ouyang, J., et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 52 (2008), 1540–1545.
8. 8 Gheorghiade, M., Konstam, M.A., Burnett, J.C. Jr., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007), 1332–1343.
9. 9 Konstam, M.A., Gheorghiade, M., Burnett, J.C., et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial. JAMA 297 (2007), 1319–1331.
10. 10 Hauptman, P.J., Burnett, J., Gheorghiade, M., et al., EVEREST Investigators. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 19 (2013), 390–397.
11. 11 Otsuka, T., Sakai, Y., Ohno, D., Murasawa, T., Sato, N., Tsuruoka, S., The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol 17 (2013), 834–838.
12. 12 Vaduganathan, M., Gheorghiade, M., Pang, P.S., et al., on behalf of the EVEREST Investigators. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med 13 (2012), 415–422.
13. 13 Matsue, Y., Suzuki, M., Torii, S., et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 22 (2016), 423–432.
14. 14 Felker, G.M., Mentz, R.J., Adams, K.F., et al. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF Trials. Circ Heart Fail 8 (2015), 997–1005.
15. 15 O'Connor, C.M., Starling, R.C., Hernandez, A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 (2011), 32–43.
16. 16 Packer, M., Colucci, W., Fisher, L., et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. J Heart Fail 1 (2013), 103–111.
17. 17 Kociol, R.D., McNulty, S.E., Hernandez, A.F., et al., NHLBI Heart Failure Network Steering Committee and Investigators. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 6 (2013), 240–245.
18. 18 Felker, G.M., Mentz, R.J., Cole, R., et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol, 2016 Sep 13 [E-pub ahead of print].
19. 19 Pruszczynski, W., Vahanian, A., Ardaillou, R., et al. Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure. J Clin Endocrinol Metab 58 (1984), 599–605.
20. 20 Blair, J.E., Pang, P.S., Schrier, R.W., et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 32 (2011), 2563–2572.
21. 21 Metra, M., Davison, B., Bettari, L., et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 5 (2012), 54–62.
22. 22 Gheorghiade, M., Gattis, W.A., O'Connor, C.M., et al., Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004), 1963–1971.